Synlogic's Experimental Drug Lowers Urinary Oxalate In Gastric Bypass Patients

Synlogic Inc's SYBX SYNB8802 has demonstrated proof of concept through a clinically significant lowering of urinary oxalate in a Phase 1b study in patients with a history of gastric bypass surgery.
The 38% urinary oxalate reduction observed at the 3x10 11 live cell dose three times a day exceeds the level of urinary oxalate reduction (-20%) associated with reduced risk of kidney stones in analyses based on observational data.
SYNB8802 was generally well tolerated.
Related: Synlogic Touts Positive Data From Rare Inherited Disorder Trial, Pivotal Study To Start Next Year.
There were no serious adverse events (SAEs). All GI-related adverse events (AEs) were mild.
In addition to the completed SYNB8802-CP-002 study, SYNB8802 is also being evaluated in an ongoing outpatient study (SYNB8802-CP-001).
"In addition, this important milestone represents the third positive clinical data readout this year in three different diseases, following our positive Phase 2 results for SYNB1934 for phenylketonuria and positive Phase 1 results for SYNB1353 for homocystinuria," said Aoife Brennan, President & CEO.
Price Action: SYBX shares are up 2.94% at $0.70 on the last check Thursday.